ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER Drug Patent Profile

Which patents cover Isolyte M In Dextrose 5% In Plastic Container, and what generic alternatives are available?

Isolyte M In Dextrose 5% In Plastic Container is a drug marketed by B Braun and is included in one NDA.

The generic ingredient in ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER is dextrose; potassium chloride; potassium phosphate, dibasic; sodium acetate; sodium chloride. There are nine drug master file entries for this compound. Additional details are available on the dextrose; potassium chloride; potassium phosphate, dibasic; sodium acetate; sodium chloride profile page.

Summary for ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER

US Patents:	0
Applicants:	1
NDAs:	1
Clinical Trials:	1
DailyMed Link:	ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER at DailyMed

Recent Clinical Trials for ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of New Mexico	Phase 2

See all ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER clinical trials

US Patents and Regulatory Information for ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
B Braun	ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER	dextrose; potassium chloride; potassium phosphate, dibasic; sodium acetate; sodium chloride	INJECTABLE;INJECTION	019870-001	Jun 10, 1993		DISCN	No	No

Market and Financial Outlook for ISOLYTE M in Dextrose 5% (Plastic Container)

Last updated: March 22, 2026

What Is the Market Position of ISOLYTE M?

ISOLYTE M, a sterile isotonic solution of dextrose 5% in plastic containers, is primarily used for fluid replacement and nutritional support in clinical settings. The product is manufactured and marketed by Baxter International Inc. It falls within the broader category of parenteral nutrition solutions and IV fluids.

Market Size and Growth

• The global IV fluids market was valued at approximately USD 13.7 billion in 2022.
• Compound annual growth rate (CAGR) from 2023 to 2030 projected at 6.3% (Research and Markets, 2023).
• Dextrose-based solutions, including ISOLYTE M, constitute roughly 23% of the IV fluids market.
• The segment is driven by increasing prevalence of dehydration, metabolic disorders, and surgical procedures requiring fluid therapy.

Competitive Landscape

Key competitors include:

Company	Major Products	Market Share (Estimated)
Baxter International	ISOLYTE M, Plasma-Lyte	45%
B. Braun Medical	Sterofund, TrophAmix	25%
Fresenius Kabi	Flexitrate, Reso IV	15%
Others	Various regional products	15%

Market dominance lies with Baxter, especially in North America and Europe.

What Are the Key Drivers and Challenges?

Drivers:

• Rising incidence of chronic diseases necessitating nutritional support.
• Expanding hospital infrastructure and outpatient care.
• Regulatory approval for new indications and formulations.

Challenges:

• Pricing pressures from healthcare systems.
• Strict regulatory requirements across regions.
• Competition from generic manufacturers and alternative IV solutions.

What Are the Financial Trajectories for ISOLYTE M?

Revenue Trends

• Baxter reported USD 12.5 billion in total revenues for 2022.
• IV fluids and IV solutions contributed approximately USD 3 billion.
• ISOLYTE M is a significant product within this division; specific sales data is proprietary but estimated to be growing at 4-6% annually.

Cost Dynamics

• Manufacturing costs include high-grade raw materials, sterile fill-finish operations, and quality assurance.
• Market expansion efforts focus on emerging markets, where average selling prices are lower, but volumes are increasing.

Commercial Strategy

• Greater focus on hospital system contracts and direct sales.
• Expansion into outpatient and home healthcare markets.
• Formulation improvements, such as pre-mixed versions, increase market penetration.

What Are Future Financial Outlooks and Trends?

• Expected compound annual growth rate (CAGR) for ISOLYTE M sales ranges between 4-6% up to 2028.
• Expansion into emerging markets could accelerate revenue growth.
• Regulatory approvals for additional indications (e.g., pediatric use) may offer new revenue streams.
• Cost control and manufacturing efficiency improvements could optimize profit margins.

What Are Regulatory and Policy Factors Impacting Market Dynamics?

• US FDA and European EMA approval processes influence market entry and product modifications.
• Price regulations in key markets such as Europe and certain Asian countries can impact profitability.
• Patent protections or lack thereof influence competitive dynamics. Baxter holds patents linked to formulation and delivery mechanisms for certain IV solutions.

Summary of Risks and Opportunities

Risks:

• Market saturation in developed regions reduces growth.
• Pricing pressures and reimbursement policies limit profit margins.
• Supply chain disruptions affecting raw material availability.

Opportunities:

• Growing demand in emerging markets (Asia, Latin America).
• Product diversification into specialized nutritional solutions.
• Increasing hospital adoption driven by aging populations.

Key Takeaways

• ISOLYTE M operates within a large and growing IV fluids market, with Baxter leading.
• Growth is driven by healthcare infrastructure expansion and demographic factors.
• Financial performance hinges on volume growth, pricing strategies, and regulatory conditions.
• Future revenue gains depend on expanding into new markets, product innovation, and efficiency improvements.

FAQs

1. What is the main use of ISOLYTE M?
   It provides fluid and nutritional replacement in hospitals and clinics, primarily for dehydration and metabolic support.

2. How does Baxter's market share influence ISOLYTE M sales?
   Baxter's estimated 45% market share in IV solutions supports significant sales volume for ISOLYTE M globally.

3. What are the main competitors to ISOLYTE M?
   B. Braun and Fresenius Kabi produce competing IV solutions, with varying market shares.

4. Which regions show the highest growth potential?
   Emerging markets such as China, India, and Latin America are prioritized for expansion.

5. How might regulatory changes affect ISOLYTE M?
   Stricter approval standards could delay new indications or formulations, while favorable policies may facilitate market expansion.

---

References

1. Research and Markets. (2023). Global Intravenous (IV) Solutions Market - Growth, Trends, and Forecasts (2023-2030).
2. Baxter International Inc. Annual Report 2022.
3. MarketsandMarkets. (2022). IV Therapy Market by Product, Application, and End User—Forecast to 2027.